NASDAQ$FULC
Fulcrum Therapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported first quarter 2021 financial results and business highlights.
Fulcrum Therapeutics reported a net loss of $17.0 million for the first quarter of 2021, with collaboration revenues of $4.8 million. The company's cash, cash equivalents, and marketable securities were $143.9 million as of March 31, 2021, which is expected to fund operations into the fourth quarter of 2022.
- On track to present data from Phase 2b ReDUX4 trial with losmapimod in FSHD at virtual FSHD International Research Congress in June 2021.
- On track to report data from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in mid-2021.
- Advanced FulcrumSeek discovery efforts and strategic collaborations with Acceleron and MyoKardia.
- Christopher Morabito, M.D. has been appointed Chief Medical Officer, effective May 10, 2021.
Headline financials
Revenue & EPS history
Fulcrum Therapeutics · Revenue · Quarterly
$4.79M
Forward guidance
The company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+5.2%
Avg return
Earnings day
+6.3%
Avg return
5 days after
+12.3%
Avg return
30 days after
62%
16 / 26 earnings
Positive
+142.5%
Q2 2021
Best reaction
-54.6%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -21.1% | -23.0% | -36.3% | |
| Q3 2025 | -6.6% | -9.8% | +9.4% | |
| Q1 2025 | +13.8% | +39.0% | +78.6% | |
| Q4 2024 | +0.0% | -3.0% | -16.5% | |
| Q3 2024 | -8.8% | -16.8% | +8.8% | |
| Q2 2024 | +7.1% | +0.6% | +1.7% | |
| Q1 2024 | +5.9% | +1.1% | +3.2% | |
| Q4 2023 | +6.1% | +12.9% | -3.0% | |
| Q3 2023 | +16.2% | -2.5% | +38.2% | |
| Q2 2023 | +3.4% | +5.5% | +49.7% | |
| Q1 2023 | +16.2% | -0.6% | -7.6% | |
| Q4 2022 | -28.0% | -36.6% | -62.0% | |
| Q3 2022 | +23.9% | +27.3% | +9.4% | |
| Q2 2022 | +8.4% | -6.2% | +7.1% | |
| Q1 2022 | -12.5% | -4.1% | -3.8% | |
| Q4 2021 | +17.4% | +37.8% | +113.9% | |
| Q3 2021 | -2.3% | -4.9% | -31.5% | |
| Q2 2021 | +142.5% | +175.3% | +233.9% | |
| Q1 2021 | +4.1% | +3.7% | -13.2% | |
| Q4 2020 | -17.7% | -17.4% | -17.8% | |
| Q3 2020 | +8.6% | +16.9% | +22.3% | |
| Q2 2020 | -54.6% | -55.5% | -54.7% | |
| Q1 2020 | +7.9% | +18.9% | +16.5% | |
| Q4 2019 | -2.2% | -27.8% | -49.4% | |
| Q3 2019 | +1.3% | +27.7% | +48.9% | |
| Q2 2019 | +7.2% | +6.1% | -25.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro